|
Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole Clinical research trials and Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole. Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole clinical trial. Participants frequently get the best healthcare available for their Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole  Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
For Condition: Head and Neck Neoplasms,Squamous Cell Carcinoma,Metastases, Neoplasm
Status: Terminated
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: The purpose of this clinical research study is to answer the following questions using 18F-fluoromisonidazole as an imaging agent: 1.) Do cells exist in human tumors that are at very low oxygen levels (hypoxic cells)? 2.) If hypoxic cells exist in human tumors, do they effect the ability of radiotherapy to control human tumors? And 3.) Can Positron Emission Tomography (PET scanning) detect hypoxic cells in human tumors? Hypoxic (low oxygen) cells have long been known to exist in animal tumors. It is also known that hypoxic cells are more difficult to eliminate with radiotherapy than tumor cells at normal levels of oxygen (normoxic cells). However, the extent to which hypoxic cells limit the curability of human tumors is uncertain. To determine if hypoxic cells exist in human tumors and how hypoxic cells might influence the efficacy of radiotherapy, this study involves direct measurements of oxygen levels in human tumors compared to the tumor uptake of the experimental drug, 18F-fluromisonidazole (18F-FMISO), visualized with PET scanning. 18F-fluoromisonidazole has been used with PET imaging to tell the difference between growing tumors which have high and low oxygen content. Before beginning radiotherapy, a PET scan (series of pictures, 20 min. scan) will be performed at 2 hours after an intravenous injection of a small amount of radioactive traces drug, 18F-fluoromisonidazole (18F-FMISO) to observe the active hypoxia tumors areas. Upon completion of the 18F-FMISO PET scan, direct oxygen measurements will be obtained by placing a small needle into the tumor under computer tomographic (CT) guidance. The PET scan and needle measurements will be repeated every 4 weeks into the course of radiotherapy and again after the completion of radiotherapy. The measurement obtained by 18F-FMISO PET scanning (non-invasive technique) and by direct needle measurements (invasive technique) will be correlated with the eventual treatment outcome for future use.
Details:
Eligibility:
Study Type: Interventional, Diagnostic, Non-Randomized, Open Label
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Histologically proven squamous cell carcinoma of head and neck wth metastatic neck nodes greater than or equal to 2cm - Karnofsky performance status greater or equal to 60% - No prior irradiation or surgery to head/neck area - No prior chemotherapy within 1 month of participation and have recovered from associated related effects - Not pregnant - Any intercurrent medical or physiologic disorder which would prevent informed consent - Underlying medical problems which would compromise technical ability to deliver a "standard course" of radiation therapy - Patients with PT or PTT over 1.5 times normal
Total Enrollment: 45
Location and Contact Information:
University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030
United States
Additional Information:
Study ID Numbers: ID93-028;
Study Start Date: January 1994
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00038038
Other Squamous Cell Carcinoma Studies:
1. A Trial of ABI-007 in Patients with Advanced Non-Hematologic Malignancies
2. A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer
3. A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
4. Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent with Metastatic Lung Cancer
5. Magnetic-Targeted Doxorubicin in Treating Patients with Cancer Metastatic to the Liver
Related Studies:
Other Squamous Cell Carcinoma Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
|
|
|
|
|
|
|
|
